Pfizer Inc. (NYSE:PFE) has been assigned a consensus rating of “Hold” from the fifteen analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $39.61.

A number of research analysts have recently commented on PFE shares. Royal Bank of Canada set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, September 9th. TheStreet upgraded Pfizer from a “c+” rating to a “b” rating in a research note on Monday, June 1st. Mizuho reissued a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research report on Tuesday. UBS Group lifted their price objective on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Finally, Barclays dropped their price objective on Pfizer from $37.00 to $35.00 in a research note on Monday, June 1st.

Shares of NYSE:PFE traded down $0.06 during midday trading on Friday, hitting $36.90. The company’s stock had a trading volume of 876,801 shares, compared to its average volume of 29,486,596. Pfizer has a fifty-two week low of $27.88 and a fifty-two week high of $40.97. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42. The stock has a market capitalization of $205.38 billion, a price-to-earnings ratio of 14.69, a PEG ratio of 2.91 and a beta of 0.67. The stock’s 50 day simple moving average is $37.79 and its 200 day simple moving average is $35.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm had revenue of $11.80 billion for the quarter, compared to analyst estimates of $11.55 billion. During the same quarter last year, the firm posted $0.80 EPS. The company’s revenue was down 11.0% on a year-over-year basis. As a group, analysts anticipate that Pfizer will post 2.89 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 31st were given a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 4.12%. The ex-dividend date of this dividend was Thursday, July 30th. Pfizer’s dividend payout ratio is 51.53%.

In related news, Director Ronald E. Blaylock purchased 13,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were bought at an average price of $38.55 per share, with a total value of $501,150.00. Following the purchase, the director now directly owns 4,000 shares in the company, valued at approximately $154,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.08% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. NewSquare Capital LLC grew its position in Pfizer by 0.4% during the second quarter. NewSquare Capital LLC now owns 60,418 shares of the biopharmaceutical company’s stock worth $1,976,000 after buying an additional 266 shares in the last quarter. Aevitas Wealth Management Inc. boosted its holdings in shares of Pfizer by 1.7% in the 2nd quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock valued at $520,000 after purchasing an additional 269 shares in the last quarter. Cutter & CO Brokerage Inc. grew its position in Pfizer by 2.0% in the second quarter. Cutter & CO Brokerage Inc. now owns 13,695 shares of the biopharmaceutical company’s stock valued at $448,000 after acquiring an additional 274 shares during the last quarter. Beaumont Asset Management L.L.C. raised its stake in Pfizer by 1.3% during the second quarter. Beaumont Asset Management L.L.C. now owns 21,244 shares of the biopharmaceutical company’s stock worth $694,000 after acquiring an additional 276 shares in the last quarter. Finally, Dividend Assets Capital LLC lifted its holdings in shares of Pfizer by 0.9% in the second quarter. Dividend Assets Capital LLC now owns 30,606 shares of the biopharmaceutical company’s stock worth $1,001,000 after acquiring an additional 278 shares during the last quarter. 69.08% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.